- Adjuvant chemotherapy (ACT) after stereotactic body radiotherapy (SBRT) was associated with worse OS in patients with T1-T3N0M0 NSCLC.
- Patients with large tumors (≥4 cm) had similar survival with or without post-SBRT ACT.
Why this matters
- ACT is routinely offered after surgery, but benefit after definitive SBRT is unclear.
- ACT extends survival after surgery, but not after definitive SBRT, in patients with large tumors.
- 24,011 patients from the National Cancer Database with T1-T3N0M0 NSCLC who received definitive SBRT.
- Median follow-up 32.5 months.
- Funding: None.
- ACT within 8 weeks of SBRT was received by 1.3% overall and by 3.4% of patients with tumors ≥4 cm (n=2323).
- ACT was associated with significantly worse OS overall (28.0 vs 36.5 months (aHR, 1.22; P=.005).
- After propensity matching, ACT was associated with worse OS overall (28.0 vs 47.7 months; HR, 1.60; P<.0001>
- For tumors ≥4 cm, 3-year OS similar with and without ACT (38.2% vs 33.0%; P=.81).
- Retrospective study.